Abstract: Disclosed are methods and devices comprising an elongated probe for the in vivo detection of meconium in amniotic fluid held in an amniotic sac based on detecting the presence of Zinc-coproporphyrin I (ZnCP). ZnCP is excited at approximately 405 nm and emits characteristic fluorescence, centered at about 580 nm and less intensely at 630 nm.

Abstract: Disclosed are methods and devices useful for imaging blood-containing tissue, for example for angiography, especially retinal angiography, whereby an image is generated by dividing pixels of an image acquired at some wavelength range by corresponding pixels of an image acquired at a different wavelength range. In some embodiments, a first wavelength range includes predominantly light having wavelengths between about 400 nm and about 620 nm and a second wavelength range includes predominantly light having wavelengths between about 620 nm and about 800 nm.

Abstract: A device for manipulating a body part, comprises: a) an elongated guide instrument provided with a tip suitable to be positioned in close juxtaposition with a tissue at a desired location of the said body part; and b) a suction channel terminating in or near said tip.

Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.

Abstract: Disclosed are methods useful for providing information useful in the diagnosis of gastrointestinal abnormalities as well as ingestible devices useful for providing information useful in the diagnosis of gastrointestinal abnormalities.

Abstract: A hybridoma cell which has been deposited under ATCC Accession Number PTA-9974 is disclosed. Also provided are Antibodies and methods of using same.

Abstract: Provided are methods of treating autoimmune diseases by administering to the subject a therapeutically effective amount of a quinolone compound such as 2-(4-methyl-1,4-diazepan-1-yl)-N-((5-methylpyrazin-2-yl)methyl)-5-oxo-5H-benzo[4,5]thiazolo[3,2-a][1,8]naphthyridine-6-carboxamide (CX-5461). Also provided are methods of monitoring efficiency of treatment of the quinolone compound by determining the expression level of at least one gene of the RNA polymerase I pathway.

Abstract: Provided is a method for improving day photopic vision and/or cone-derived visual field and visual function in a subject suffering from a retinal disease or trauma including administering to the subject a pharmaceutically effective amount of crude Dunaliella powder. Also provided is a method for improving night vision and/or rod derived visual field in a subject suffering from a retinal disease including administering to the subject a pharmaceutically effective amount of crude Dunaliella powder. A pharmaceutical composition for improving day vision and/or visual field in a subject suffering from a retinal disease including crude Dunaliella powder is also provided.

Abstract: A method of reprogramming a differentiated renal cell towards a progenitor phenotype is disclosed. The method comprises up-regulating in the differentiated renal cell an expression of at least one pluripotency associated gene and/or at least one renal stem cell associated gene, thereby reprogramming the differentiated renal cell towards a progenitor phenotype. Cell populations generated thereby and uses thereof are also disclosed.

Abstract: A method of monitoring heat damage to a tissue during a heat ablation procedure is disclosed. The method comprising: providing images of the tissue, extracting at least one parameter being indicative of a biological response to heat, and using the parameter(s) for determining the heat damage to the tissue.

Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.

Abstract: A radiotherapy system is disclosed. The radiotherapy system comprises an electron beam generator for generating an electron beam and a magnetic field generator for generating a magnetic field. In some embodiments of the present invention, the system further comprises a controller for controlling the electron beam and the magnetic field generators such that the electron beam is dynamically shifted and the magnetic field is dynamically redirected synchronously with the shifting.

Abstract: Disclosed are methods of subretinal delivery of therapeutic compositions to the eye of a mammal. Also disclosed are devices useful for the subretinal delivery of therapeutic compositions to the eye of a mammal.

Abstract: A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8+CD28?CD152? signature in a sample of the subject, wherein a frequency of TILs having the CD8+CD28?CD152? signature above a predetermined level is indicative of a positive responsiveness to cancer treatment. Other signatures reflecting responsiveness to cancer treatment are also disclosed. In addition, methods of treating cancer based on these signatures are also disclosed.

Abstract: Provided is a method for improving day photopic vision and/or cone-derived visual field and visual function in a subject suffering from a retinal disease or trauma including administering to the subject a pharmaceutically effective amount of crude Dunaliella powder. Also provided is a method for improving night vision and/or rod derived visual field in a subject suffering from a retinal disease including administering to the subject a pharmaceutically effective amount of crude Dunaliella powder. A pharmaceutical composition for improving day vision and/or visual field in a subject suffering from a retinal disease including crude Dunaliella powder is also provided.

Abstract: A method of diagnosing fibrosis in a subject is provided, comprising the steps of: determining a level of PCPE in a body fluid sample obtained from said subject; and detecting an increased level of PCPE in said body fluid sample relative to a normal control level of PCPE, wherein said increased level of PCPE relative to normal control is indicative of fibrosis in said subject. Furthermore, methods for evaluating the pharmacological efficacy of a drug or a drug candidate in treatment of fibrosis in a patient and for monitoring change of fibrosis in a subject are provided.

Abstract: The invention provides a device for delivering electromagnetic radiation to a limbal area of an eye that transforms one or more beams of electromagnetic radiation that are incident on a first side into one or more emitted beams of the electromagnetic radiation where the one or more beams are arrayed in a cylindrical array, an array of one or more beams each beam having a cross sectional shape of a circular arc or an array comprising a beam having an annular cross section. The invention also provides a system for delivering electromagnetic radiation to the limbal area of an eye that includes one or more devices of the invention and a source of electromagnetic radiation. The system may be used in the treatment of glaucoma.

Abstract: The present invention relates to methods for diagnosing, staging, prognosticating and treating melanoma based on evaluating the expression of specific patterns of oncogenic or suppressive microRNA (miR) molecules in a patient in need thereof.

Abstract: The present invention provides a unique profile of volatile organic compounds as breath biomarkers for lung cancer. The present invention further provides the diagnosis, prognosis and monitoring of lung cancer or predicting the response to an anti-cancer treatment through the detection of the unique profile of volatile organic compounds indicative of lung cancer at its various stages.

Abstract: In accordance with the present disclosure there are provided iron oxide nanoparticles for use in the treatment of non-infectious inflammatory disorders.